Do you have enough to be track ?? after NSA?? now Oracle...Google...AAPL ???
Cramer was an Hedge Funds trader....He know how to $%$#$@$!@ peoples....but for now he is right on the trade side......buy cheaper soon or later....but not now....under $85.....!!!
BUT Gilead sell Solvadi tx $84000 in US but $900 in India after buying the small cap who create (Solvadi) for a cheap $11B ??? Greed =GILD !!!
If this goes under $92 get out!!!
The next question asks if Gilead Sciences (GILD) is overdone at $97, and Cramer says that while he has been behind Gilead (along with Regeneron (REGN) , Biogen Idec (BIIB) , and Celgene (CELG) ), he now needs to wait because it is time to reassess after the large gains there.
Must Watch: Jim Cramer Answers Twitter Questions on Spinoffs, Gilead and Vale
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Cramer points to TheStreet's Adam Feuerstein's article, in which he says the Express Scripts (ESRX) hepatitis C pharmacy deal with AbbVie (ABBV) could be a game-changer. Therefore, Cramer plans to wait and see how this develops.
Sentiment: Strong Sell
lol keep buying......we are selling to you...lol
The great irony: it looks like the super-expensive hepatitis C drugs, which became symbols of high drug costs, are actually going to lower the cost of treating a hepatitis C patient. According to a piece in the Journal of the American Medical Association by Troyen Brennan, the chief medical officer at CVS, the cost of treating a hepatitis C patient with the regiment tha was available before Sovaldi became available – a combination of Incivek, a drug sold by Vertex, interferon and ribavirin — was between $112,000 for a 24 week treatment and $143,000 for a 48 week treatment, with lower cure rates.
What’s really changed is that the drugs can now be used in all of the as many as three million people who have hepatitis C, many of them without knowing it. The question is how do you decide who gets a cure, who doesn’t, and who should settle for a cure that’s a little less pleasant.
...AbbVie's new hepatitis C drug gets boost
The price war over hepatitis C drugs continues, after Express Scripts (NASDAQ:ESRX) announced that it will only cover AbbVie's (NYSE:ABBV) newly approved Viekira Pak, which received clearance from the FDA on Friday.The move will help the drug maker take market share away from Gilead Sciences (NASDAQ:GILD) and J&J (NYSE:JNJ), which make blockbuster hep C drugs, including Sovaldi, Harvoni and Olysio.
Insider Transactions Reported - Last Two Years
Date Insider Shares Type Transaction Value*
Dec 8, 2014 MILLIGAN JOHN F
146,823 Direct Sale at $105.25 - $106.55 per share. 15,549,0002
Dec 8, 2014 MILLIGAN JOHN F
146,823 Direct Option Exercise at $8.01 per share. 1,176,052